HOF Capital

Congratulations to Ben Lamm and the rockstar team at Colossal Biosciences for the incredible scientific milestones leading to this round! We’re excited for the continued journey on their mission to advance de-extinction and species preservation. https://lnkd.in/gtK5Qbdx

Delighted to share the double-expansion of our collaboration with Pfizer, expanding on AI-driven small molecule drug design as well as broadening into payload design for Antibody-Drug Conjugates (ADCs). This expanded collaboration spotlights the versatility and validation of Proton, our drug discovery platform. Personally, I'm excited by the growth of PostEra from pioneering AI research in medicinal chemistry to a TechBio, with an internal pipeline on Women's Health and reproductive endocrinology, and multiple big pharma partnerships. As a young company these deals have driven $50M in revenue and today we're profitable as a result.  ➡ Endpoints News Story: https://lnkd.in/ex7UbcYr

#NEWS: Today, PostEra is excited to announce a double-expansion of our collaboration with Pfizer. We'll be expanding our existing AI Lab partnership, while also launching a new partnership to develop novel payloads for Antibody-Drug-Conjugates (ADCs).   🧪 AI Lab: 3 years ago PostEra began to apply our latest advances in machine learning to a series of small molecule programs at Pfizer. The teams called this the AI Lab as the intent was to provide a relatively autonomous environment for AI to prove (or not prove) it's worth. After a series of successes, Pfizer went on to nominate the maximum number of programs into the AI Lab. Given the exciting progress and great partnership between the two teams, the AI Lab will now be expanded to include additional programs.   ⛓️💥 ADCs: Arguably one of the hottest spaces in recent years, ADCs can offer a best-of-both-worlds by allowing for a very targeted delivery of a very potent agent; Pfizer's $43Bn acquisition of Seagen speaks to just how much excitement surrounds this technology. Yet there is much to be done to improve the current states of ADCs and we're excited at PostEra to apply our AI to tackle one of those challenges -- the design of novel payloads (think the D of ADCs).   🏅🏅🏅 This expansion represents the 3rd deal PostEra and Pfizer have done together. Along with our other flagship AI partners, Amgen and The National Institutes of Health, these partnerships form the cornerstone of how we support the development of new cures for diseases outside our core internal pipeline.   Finally, a huge thanks to the brilliant scientists, BD, and Legal teams at Pfizer who worked with us to make this happen. ➡️ Read More: https://lnkd.in/gqiKWbU4   #MachineLearning #AIinHealthcare #Pharma #DrugDiscovery #Startup #Biotech #AI

#NEWS: Today we're excited to announce a double-expansion of our collaboration with Pfizer. We'll be expanding our existing AI Lab partnership, while also launching a new partnership to develop novel payloads for Antibody-Drug-Conjugates (ADCs). 🧪 AI Lab: 3 years ago PostEra began to apply our latest advances in machine learning to a series of small molecule programs at Pfizer. The teams called this the AI Lab as the intent was to provide a relatively autonomous environment for AI to prove (or not prove) it's worth. After a series of successes, Pfizer went on to nominate the maximum number of programs into the AI Lab. Given the exciting progress and great partnership between the two teams, the AI Lab will now be expanded to include additional programs. ⛓️💥 ADCs: Arguably one of the hottest spaces in recent years, ADCs can offer a best-of-both-worlds by allowing for a very targeted delivery of a very potent agent; Pfizer's $43Bn acquisition of Seagen speaks to just how much excitement surrounds this technology. Yet there is much to be done to improve the current states of ADCs and we're excited at PostEra to apply our AI to tackle one of those challenges -- the design of novel payloads (think the D of ADCs). 🏅🏅🏅 This expansion represents the 3rd deal PostEra and Pfizer have done together. Along with our other flagship AI partners, Amgen and The National Institutes of Health, these partnerships form the cornerstone of how we support the development of new cures for diseases outside our core internal pipeline. Finally, a huge thanks to the brilliant scientists, BD, and Legal teams at Pfizer who worked with us to make this happen. ➡️ Read More: https://lnkd.in/g-FtVGJm #MachineLearning #AIinHealthcare #Pharma #DrugDiscovery #Startup #Biotech #AI

Big news today… We’re thrilled to announce that Vooma has secured $16.6M in Seed and Series A funding from Craft Ventures, Index Ventures, and other leaders in the logistics industry. Vooma was started to empower the women and men who keep America’s economy running. Our aim is to give them the best AI tools to win and execute more freight. Everyday logistics operators face hundreds of repetitive tasks that pull them away from building relationships and solving tough challenges. We believe we can change that. Today we’re also announcing Vooma Agents – the first multi-channel AI platform built for logistics. It’s the foundation for building autonomous agents with freight expertise that can execute complex workflows across email, voice and text. We’re also introducing Vooma Voice, which gives Vooma Agents the ability to make and receive calls - critical to many freight workflows. We’re grateful to our customers, partners, Voomers and investors for believing in our vision, especially Y Combinator, Definition, HOF Capital, Operator Stack Fund and Soma Capital for your support in the round. We’re just getting started. Thank you to Grace Sharkey 🚛🤖💙 and the FreightWaves team for covering the news. Check out the comments for links to the article and our blog post for more details. Want to join a rocketship helping move forward a critical industry? Reach out - we’re hiring across roles. Let’s Vooma!

Congrats to Warp on being selected as one of the Cloud 100 Rising Stars 2024! Since day one, we’ve been big believers in the customer obsession and lightning-fast execution of Ayush and the Warp team. We’re excited to be part of their journey to simplify payroll so that their customers, startups of all sizes, can spend more time building the future.

Today, I'm excited to announce we have raised $40m Series A It's been an incredible journey so far, we are just getting started, give us a couple of years, we've got some big plans. Techcrunch: https://lnkd.in/dkE2WvvM I'm super proud of our team: 34x growth in 20 months, 10x revenue growth in the past 10 months and profitable. I'm grateful for Nicolas Esteves and Nicolai Eddy who I have had the privilege of building NALA with the past 4 years, they have put their life into building this company with me with countless late nights, weekends constantly trying to execute on our bold mission to build payments for the next billion! NALA x RAFIKI #1PercentBuilt.

Congratulations to our portfolio company BillionToOne on serving more than 500K patients thus far, growing from $0M to $125M of annualized revenue over approximately the past 4 years, and raising an oversubscribed $130M Series D round at a greater than $1B valuation! We're fortunate to have partnered with BillionToOne since its Series A round in 2019, and we're excited about BillionToOne's quest to help millions of patients with its best-in-class prenatal tests and liquid biopsy products in the future!

StyleAI grew from $0 to $4M in 12 months. We are a small, close-knit team ambitious to automate digital marketing for every small business. As the company grows fast, we look for someone to help with business development and operations. If you enjoy working in a fast-paced environment and are result-oriented, check out the company's website and the career page. StyleAI - https://usestyle.ai/ Careers page - https://lnkd.in/g_BBn4aN

Earlier this month, we landed on the front page of Business Insider Startups. (Want to be a part of something big? We're hiring! Link in the comments.)